98 related articles for article (PubMed ID: 11825062)
1. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
2. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
3. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
[TBL] [Abstract][Full Text] [Related]
5. Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation.
Kehar M; Sen Sarma M; Seetharaman J; Jimenez Rivera C; Chakraborty P
Can Liver J; 2024 Feb; 7(1):54-63. PubMed ID: 38505790
[TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of pyrazole-benzothiadiazole hybrid as human HPPD inhibitors.
Dong J; Xiao H; Chen JN; Zheng BF; Xu YL; Chen MX; Yang WC; Lin HY; Yang GF
Structure; 2023 Dec; 31(12):1604-1615.e8. PubMed ID: 37794595
[TBL] [Abstract][Full Text] [Related]
7. Long-term culture of genome-stable bipotent stem cells from adult human liver.
Huch M; Gehart H; van Boxtel R; Hamer K; Blokzijl F; Verstegen MM; Ellis E; van Wenum M; Fuchs SA; de Ligt J; van de Wetering M; Sasaki N; Boers SJ; Kemperman H; de Jonge J; Ijzermans JN; Nieuwenhuis EE; Hoekstra R; Strom S; Vries RR; van der Laan LJ; Cuppen E; Clevers H
Cell; 2015 Jan; 160(1-2):299-312. PubMed ID: 25533785
[TBL] [Abstract][Full Text] [Related]
8. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
10. Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.
van Ginkel WG; van Vliet D; van der Goot E; Faassen MHJR; Vogel A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31623189
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky JM; Singh R; Ficicioglu C; van Karnebeek CDM; Grompe M; Mitchell G; Waisbren SE; Gucsavas-Calikoglu M; Wasserstein MP; Coakley K; Scott CR
Genet Med; 2017 Dec; 19(12):. PubMed ID: 28771246
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the management of tyrosinaemia type 1.
de Laet C; Dionisi-Vici C; Leonard JV; McKiernan P; Mitchell G; Monti L; de Baulny HO; Pintos-Morell G; Spiekerkötter U
Orphanet J Rare Dis; 2013 Jan; 8():8. PubMed ID: 23311542
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
[TBL] [Abstract][Full Text] [Related]
14. Bipotent transitional liver progenitor cells contribute to liver regeneration.
Pu W; Zhu H; Zhang M; Pikiolek M; Ercan C; Li J; Huang X; Han X; Zhang Z; Lv Z; Li Y; Liu K; He L; Liu X; Heim MH; Terracciano LM; Tchorz JS; Zhou B
Nat Genet; 2023 Apr; 55(4):651-664. PubMed ID: 36914834
[TBL] [Abstract][Full Text] [Related]
15. Integrated Network Pharmacology Analysis and Serum Metabolomics to Reveal the Anti-malaria Mechanism of Artesunate.
Wang F; Song J; Yan Y; Zhou Q; Li X; Wang P; Yang Z; Zhang Q; Zhang H
ACS Omega; 2022 Sep; 7(35):31482-31494. PubMed ID: 36092633
[TBL] [Abstract][Full Text] [Related]
16. In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.
Nicolas CT; VanLith CJ; Hickey RD; Du Z; Hillin LG; Guthman RM; Cao WJ; Haugo B; Lillegard A; Roy D; Bhagwate A; O'Brien D; Kocher JP; Kaiser RA; Russell SJ; Lillegard JB
Nat Commun; 2022 Aug; 13(1):5012. PubMed ID: 36008405
[TBL] [Abstract][Full Text] [Related]
17. Fumarylacetoacetate hydrolase gene as a knockout target for hepatic chimerism and donor liver production.
Larson EL; Joo DJ; Nelson ED; Amiot BP; Aravalli RN; Nyberg SL
Stem Cell Reports; 2021 Nov; 16(11):2577-2588. PubMed ID: 34678209
[TBL] [Abstract][Full Text] [Related]
18. Genetically blocking
Gu P; Yang Q; Chen B; Bie YN; Liu W; Tian Y; Luo H; Xu T; Liang C; Ye X; Liu Y; Tang X; Gu W
Mol Ther Methods Clin Dev; 2021 Jun; 21():530-547. PubMed ID: 33997102
[TBL] [Abstract][Full Text] [Related]
19. Amino acid metabolism and autophagy in skeletal development and homeostasis.
Suzuki A; Iwata J
Bone; 2021 May; 146():115881. PubMed ID: 33578033
[TBL] [Abstract][Full Text] [Related]
20. The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism.
Thompson WS; Mondal G; Vanlith CJ; Kaiser RA; Lillegard JB
Expert Opin Orphan Drugs; 2020; 8(7):245-256. PubMed ID: 33224636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
